SPORE Core B. Pathology and Tissue Resources Core. The Tissue Resources and MolecularPathology Core will provide routine and innovative tissues and materials, as well as conventional andmolecular pathology assistance, essential for achieving the aims of the SPORE projects. Routine materialsinclude tumors and non-malignant lung specimens and tumor cell lines. Over 2,500 well-characterizedtumors with annotated clinical data and 200 cell lines have been banked, and over 15,000 aliquots of tumoror cell line pellets, RNA or DNA or paraffin sections are available to SPORE investigators. State-of-artmolecular pathology facilities devoted to lung cancer translational research directed by experienced lungcancer molecular pathologists are available.
Our Aim 1 is to collect, process, store, catalog and distributetissues, cells and blood specimens, both malignant and non-malignant, and relevant clinico-pathologic data,as requested by the various component projects of the SPORE program.
Aim 2 is to develop and utilizeinnovative or routine tissue and cell resources that will aid in the successful completion of the SPOREprogram aims. Innovative materials include: a) cell pellets and tissue microarrays (TMAs) and high throughputimage analysis of in situ techniques, b) new lung cancer cell lines and lung cancer xenografts madedirectly from patient specimens, c) new immortalized and non-immortalized human bronchial epithelial cells(HBECs) and 3-dimensional organotypic cultures.
Aim 3 is to perform and interpret tissue-based molecularmethodologies in close collaboration with the component projects of the SPORE program to satisfy theirapproved aims. This includes immunohistochemistry (IHC) information on over 90 lung cancer relevantbiomarkers on the TMAs with information stored in an image database and integrated with the clinicalannotations.
Aim 4 is to promote collaboration among investigators in this SPORE, other lung cancerSPORES, other investigators in MD Anderson Cancer Center, UT Southwestern Medical Center, and otherinvestigators nationally and internationally pursuing lung cancer relevant research. All of our five projects inthis application will utilize CORE materials. Heavy utilization of our routine and innovative materials, andclose interactions with the SPORE investigators will greatly aid the successful completion of the aims of ourSPORE proposal. The SPORE Tissue Resource Core is designed and has operated as a facility receivingsupport from several other sources beyond SPORE funding including in a manner non-overlapping withother Cancer Center activities at both MD Anderson and UT Southwestern Medical Centers. This meansthat SPORE discoveries and data have far reaching beneficial effects across the range of lung cancerresearch conducted at these two institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA070907-11
Application #
7507390
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-09-01
Project End
2013-04-30
Budget Start
2008-09-01
Budget End
2009-04-30
Support Year
11
Fiscal Year
2008
Total Cost
$214,827
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835
Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :

Showing the most recent 10 out of 1059 publications